ESCALATE

Study Type:
Interventional[Clinical Trial]

Study Design:

    Interventional Model: Sequential Assignment
  • Intervention Model Description: Lead-in open-label androgen-receptor blocker (ARB) followed by double-blind Radium-223 or placebo.
  • Estimated Enrollment: 499 participants
  • Masking: Double (Participant, Investigator)
  • Primary Purpose: Treatment
  • Official Title:
    ESCALATE, A Phase III Randomized Study Comparing Enzalutamide or Darolutamide With Radium-223 vs Enzalutamide or Darolutamide With Placebo and the Effect Upon Symptomatic Skeletal Event-Free Survival for mCRPC Patients